Bradanicline
From Wikipedia, the free encyclopedia
(Redirected from TC-5619)
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
N-[(2S,3R)-2-(Pyridin-3-ylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzofuran-2- carboxamide
|
|
| Identifiers | |
| CAS Number | 639489-84-2 |
| PubChem | CID 16727410 |
| UNII | UM3821998K  |
| ChEMBL | CHEMBL1258006 |
| Synonyms | TC-5619 |
| Chemical data | |
| Formula | C22H23N3O2 |
| Molar mass | 361.437 g/mol |
|
|
| (verify) |
Bradanicline (INN) (code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder. [1] Phase I clinical trials were completed successfully, and it was in phase II trials.[2]
In May 2011, AstraZeneca declined to exercise its right to license the compound.[3] In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults.[4] It was being studied for cognitive and memory enhancement.[5]
Bradanicline was discontinued for Alzheimer's disease and cognitive impairment in schizophrenia in late 2013.[6] It was also discontinued for ADHD, and no longer seems to be being developed.[6]
References[edit]
- ^ TC-5619 Cognitive Dysfunction in Schizophrenia
- ^ Rethinking Schizophrenia
- ^ Targacept retains full development rights for TC-5619
- ^ Targacept ends development of ADHD drug
- ^ "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). November 27, 2013.
- ^ a b http://adisinsight.springer.com/drugs/800026693
|
|
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
